DA
TPTX

Duality Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Duality Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,498
Closed -$443K – 923
2022
Q1 		$443K Sell
16,498
-13,911
-46% -$467K 0.05% 494
2021
Q4 		$1.45M Buy
+30,409
New +$1.36M 0.16% 228
2021
Q2 		– Sell
-27,253
Closed -$2.58M – 764
2021
Q1 		$2.58M Buy
+27,253
New +$3.24M 0.22% 149

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Duality Advisers's TPTX Position: Q2 2022 in Review

Duality Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 16,498 shares — an estimated $443K sold.

Duality Advisers first reported a position in TPTX in Q1 2021 and held it in 3 quarters. The position peaked at $2.58M in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Duality Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Duality Advisers sold 16,498 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $443K.
  • Duality Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Duality Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $2.58M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.